Business Context and Reporting Period
This Form 8-K was filed by BCTG Acquisition Corp. (not Tango Therapeutics, Inc.) on October 6, 2020. The registrant is a Delaware corporation and an emerging growth company. The filing reports a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors from five to six.
- New Appointment: James B. Avery was appointed as a Class 3 director.
Management Commentary and Background
Management stated that Mr. Avery's background in strategic corporate matters and capital markets provides valuable expertise for the Company. His professional history includes:
- Senior Managing Director at Tavistock Group (since July 2014).
- Managing Director and Co-Founder of GCA Savvian (2003–2014).
- 10 years at Morgan Stanley advising on M&A and capital markets.
- Current board memberships at Inseego Corp. and FrontWell Capital Partners.
Investor Verification Checklist
- Verify the registrant name is BCTG Acquisition Corp., not Tango Therapeutics, Inc.
- Confirm the new director's (James B. Avery) independence and potential conflicts of interest via his other board roles.
- Review the Company's charter to understand the implications of increasing the board size to six.
- Note that no financial performance data is disclosed in this specific filing.